Letter from Pew: Updates on the Unique Device Identifier System
A letter from Josh Rising, director of Pew's Medical Device Initiative, about updates on the unique device identifier system.
More infoWASHINGTON—The U.S. Senate today joined the House in passing Food and Drug Administration Safety and Innovation Act (S. 3187), a bill to support the U.S. Food and Drug Administration’s drug and device reviews.
"We commend the Senate for passing the bipartisan FDA Safety and Innovation Act, and the Health, Education, Labor and Pensions Committee for its leadership throughout this process,” said Allan Coukell, director of medical programs at the Pew Health Group.
"This legislation will, for the first time, enable the FDA to:
- Regularly inspect foreign drug manufacturing facilities, which supply 80 percent of the ingredients in our medications
- Spur the development of new antibiotics specifically to treat serious and life-threatening infections; and
- Actively monitor the safety of high-risk medical devices already on the market and promote innovation by streamlining the review process for new low- and medium-risk devices.
"We applaud Republicans and Democrats in both chambers of Congress for collaborating with each other and with businesses, consumer and patient advocates, and the medical community to develop and pass this bill. We now urge President Obama to sign and implement this legislation as swiftly as possible."
- Date added:
- Jun 26, 2012
- Contact:
- Joshua Wenderoff
- Projects:
- Antibiotics and Innovation Project, Drug Safety Project, Medical Device Initiative
- Topic:
- Medical Safety
Related Resources
Pew Comment Letter to the Senate HELP Committee on Compounding Legislation
Pew sent a comment letter to the Senate Committee on Health, Education, Labor and Pensions on the Pharmaceutical Compounding Quality and Accountability Act. This bill takes steps toward clarifying state and federal oversight of compounding, including an important increase in FDA supervision of certain activities—specifically, the compounding of sterile medicines that are shipped interstate.
More infoLetter from Pew to FDA on Postmarket Surveillance Plan
FDA recently updated the national medical device postmarket surveillance plan – listing device identification and registries as the cornerstones for effective product monitoring. In this letter, medical devices director Josh Rising applauds the agency for making unique device identifiers and registries central to this plan.More info
